ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2022
Baicalin inhibits inflammation of lipopolysaccharide-induced acute lung injury toll like receptor-4/myeloid differentiation primary response 88/nuclear factor-kappa B signaling pathway.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Dry eye disease due to meibomian gland dysfunction treated with Pinggan Yuyin Qingre formula: a stratified randomized controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Trial
- Effects of Dietary Dandelion Supplementation on Ruminal Morphology, Fermentation, Microbiome, and Inflammation in Lambs Under High-Concentrate Feeding.Animals : an open access journal from MDPI · 2026Article
- Transcriptomics and network pharmacology reveal that baicalin alleviates acute lung injury induced by H1N1 via targeting STAT1.Archives of microbiology · 2026Article
- Baicalin: bridging traditional medicine and modern science in food and functional applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Administration of a Recombinant Fusion Protein of IFN-γ and CD154 Inhibited the Infection of Chicks withVeterinary sciences · 2025Article
- Baicalin relieves complement alternative pathway activation-induced lung inflammation through inhibition of NF-κB pathway.BMC complementary medicine and therapies · 2024Article
- Baicalin and lung diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Qingfei Huoxue Decoction and Its Active Component Narirutin Alleviate LPS-Induced Acute Lung Injury by Regulating TLR4/NF-κB Pathway Mediated Inflammation.Journal of inflammation research · 2024Article
- Unraveling the protective mechanisms of Chuanfangyihao against acute lung injury: Insights from experimental validation.Experimental and therapeutic medicine · 2023Article
- Anti-inflammatory, anti-tussive effects and toxicity evaluation of Qingfei Dayuan granules.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Article
- Qinhuo Shanggan oral solution resolves acute lung injury by down-regulating TLR4/NF-Frontiers in immunology · 2023Article
- Pharmacological effects of baicalin in lung diseases.Frontiers in pharmacology · 2023Review
- The protective effects of baicalin for respiratory diseases: an update and future perspectives.Frontiers in pharmacology · 2023Review
- Recent insights into the biological functions of baicalin.EXCLI journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effect and mechanism of baicalin in the treatment of acute lung injury (ALI) by and experiments.
methodsALI was induced by instilling 10 mg/mL lipopolysaccharide (LPS) into the airway of rats. Different doses of baicalin (50 and 100 mg·kg ·d) were administered by gavage one day before modeling.
resultsBaicalin significantly reduced the permeability of the alveolocapillary membrane, alleviated tissue injury and inflammatory infiltration, and inhibited the secretion of inflammatory factors and the infiltration of neutrophils. The decline in these inflammations was related to the inhibition of the toll like receptor-4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor-kappa B (NF-κB)/nod-like receptor pyrin containing 3 (NLRP3) signaling pathway and the mitogen-activated protein kinase (MAPK) signaling pathway.
conclusionsBaicalin inhibits the secretion of inflammatory factors by inhibiting the TLR4-MyD88-NF-κB/NLRP3 pathway and the MAPK signaling pathway. Thus, it reduces lung bronchial epithelial layer, alveolar damage, and pulmonary edema as detected in the and experiments. Therefore, baicalin may be a potential preventive and therapeutic drug for ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.